Academic drug discovery centers adapt to shifts in funding sources | March 27, 2017 Issue - Vol. 95 Issue 13 | Chemical & Engineering News
Volume 95 Issue 13 | pp. 16-18
Issue Date: March 27, 2017

Academic drug discovery centers adapt to shifts in funding sources

Universities are pushing their novel molecules into clinical trials
Department: Business
Keywords: drug discovery, academic drug discovery, Vanderbilt, Scripps, Calibr, Tri-I TDI

Craig Lindsley flew out to Tulsa in November 2012 to give a talk about the research in his labs at the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) in Nashville. His host was William K. Warren Jr., a businessperson and philanthropist who had endowed the medicinal chemist’s chair at Vanderbilt University.

Lindsley walked his audience through what was then a six-year effort to develop compounds that address the cognitive challenges and tough-to-treat symptoms of schizophrenia. . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society